TransCode Therapeutics (RNAZ) Announces Strategic Expansion of its Product Portfolio
TransCode Therapeutics, Inc. (RNAZ), a leading clinical-stage oncology company committed to using its proprietary platform delivery system to defeat cancer, today announced a strategic expansion of its diverse product portfolio. New capabilities for TransCode’s TTX delivery platform are embodied in the new provisional patent application entitled, “Nanoparticles Comprising Payloads and Their In Vivo Delivery” (U.S. patent application 63/456,602 or the ‘602 application).
The therapeutic potential of RNA in oncology has remained an unrealized promise due to what is believed to be the difficulty in safely and effectively delivering oligonucleotides to tumors. Despite well documented targets that have been shown to be important for cancer onset, progression and recurrence, delivery mechanisms have fallen short in delivering RNA therapeutic payloads due to systemic inflammation, toxicity and the inability to efficiently reach their targets. Additionally, targeted delivery of therapeutic agents outside of RNA approaches has also remained a significant challenge for treatment of many other diseases besides cancer.
The technology disclosed in the ‘602 application represents an expansion of TransCode’s therapeutic delivery platform to include applicability to gene editing by repairing and/or replacement of genes using CRISPR technology and cancer vaccines using messenger RNA (mRNA).
- Advertisement -
TransCode’s CEO, Michael Dudley, said, “Our scientists have been working to expand the potential of our nanoparticle delivery system for some time in order to overcome the challenges of targeted delivery of therapies in oncology. We believe that by expanding our delivery platform and our resulting product portfolio including CRISPR, mRNA vaccines and potentially other targeted therapies outside of RNA positions the company as a platform delivery company.”
The filing of the ‘602 application directly supports TransCode’s goal of deploying the right therapy for individual cancer patients. If issued, the proposed patent would join other granted patents controlled by TransCode, including US 9,629,812 and EP 2 961 386. As part of its overall patent strategy, TransCode is actively pursuing intellectual property protection for additional components of its discovery engine built around its TTX delivery platform. The TTX platform currently comprises a hemodynamic and metabolic targeting delivery system suitable for deploying a variety of therapeutic candidates including RNAi, pattern recognition receptors, mRNA, gene repair/replacement and radiolabeled therapeutics.
Dudley added, “While our major focus is on advancing TTX-MC138, our lead therapeutic candidate targeting miR-10b, shown to be a master regulator of metastatic cell viability in a number of solid tumor types, we are excited by our platform’s expanded potential to be used more broadly for a variety of therapeutic approaches to relevant documented targets responsible for cancer onset, progression and recurrence. The approach represented by the ’602 application, if successful in development, could expand our ability to deploy the right therapy for individual patients using the therapeutic capabilities our platform offers.”